# Imfinzi® (durvalumab) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/durvalumab

> The FDA approved Imfinzi® (durvalumab), sponsored by ASTRAZENECA PLC (AZN), on May 1, 2017.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, quarter only, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | Imfinzi® (durvalumab) |
| Codes | MEDI4736 |
| Sponsor | ASTRAZENECA PLC (AZN) https://sec-api.dev/companies/azn/catalysts |
| Indications | [Non-Muscle- Invasive Bladder Cancer](https://sec-api.dev/indications/non-muscle-invasive-bladder-cancer), [Breast Cancer](https://sec-api.dev/indications/breast-cancer), [Non-Small Cell Lung Cancer](https://sec-api.dev/indications/non-small-cell-lung-cancer), [Hepatocellular Carcinoma (HCC)](https://sec-api.dev/indications/hepatocellular-carcinoma-hcc), [Hepatocellular Carcinoma](https://sec-api.dev/indications/hepatocellular-carcinoma), [Small Cell Lung Carcinoma](https://sec-api.dev/indications/small-cell-lung-carcinoma), [Biliary Tract Cancer](https://sec-api.dev/indications/biliary-tract-cancer), Papillary Renal Cell Carcinoma |
| Modality | antibody |
| FDA designations | fast track, priority review |

## Timeline

### May 1, 2017: FDA approval

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "BLA761069 ORIG-1 (Type 1 - New Molecular Entity): submission_status AP, submission_status_date 20170501, review_priority PRIORITY; sponsor_name ASTRAZENECA UK LTD; product IMFINZI (DURVALUMAB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761069%22

### March 27, 2020: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "BLA761069 SUPPL-18 (Efficacy): submission_status AP, submission_status_date 20200327, review_priority PRIORITY; sponsor_name ASTRAZENECA UK LTD; product IMFINZI (DURVALUMAB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761069%22

### November 18, 2020: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "BLA761069 SUPPL-23 (Efficacy): submission_status AP, submission_status_date 20201118, review_priority PRIORITY; sponsor_name ASTRAZENECA UK LTD; product IMFINZI (DURVALUMAB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761069%22
- openFDA Drugs@FDA: "BLA761069 SUPPL-24 (Efficacy): submission_status AP, submission_status_date 20201118, review_priority PRIORITY; sponsor_name ASTRAZENECA UK LTD; product IMFINZI (DURVALUMAB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761069%22

### February 19, 2021: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "BLA761069 SUPPL-29 (Efficacy): submission_status AP, submission_status_date 20210219, review_priority PRIORITY; sponsor_name ASTRAZENECA UK LTD; product IMFINZI (DURVALUMAB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761069%22

### September 2, 2022: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "BLA761069 SUPPL-35 (Efficacy): submission_status AP, submission_status_date 20220902, review_priority PRIORITY; sponsor_name ASTRAZENECA UK LTD; product IMFINZI (DURVALUMAB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761069%22

### October 21, 2022: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "BLA761069 SUPPL-36 (Efficacy): submission_status AP, submission_status_date 20221021, review_priority PRIORITY; sponsor_name ASTRAZENECA UK LTD; product IMFINZI (DURVALUMAB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761069%22

### November 10, 2022: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "BLA761069 SUPPL-33 (Efficacy): submission_status AP, submission_status_date 20221110, review_priority STANDARD; sponsor_name ASTRAZENECA UK LTD; product IMFINZI (DURVALUMAB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761069%22

### June 14, 2024: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "BLA761069 SUPPL-45 (Efficacy): submission_status AP, submission_status_date 20240614, review_priority STANDARD; sponsor_name ASTRAZENECA UK LTD; product IMFINZI (DURVALUMAB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761069%22

### July 25, 2024: FDA advisory committee meeting

- Status: completed, positive. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- FDA advisory committee calendar: "The Committee will discuss supplemental biologics license application (sBLA) 761069/S-043, for IMFINZI (durvalumab) injection, submitted by AstraZeneca UK Limited. The proposed indication (use) is IMFINZI in combination with platinum-containing chemotherapy as neoadjuvant treatment, followed by IMFINZI as monotherapy after surgery, for the treatment of adult patients with resectable (tumors ≥ 4 cm and/or node positive) non-small cell lung cancer (NSCLC) and no known epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) rearrangements." https://www.fda.gov/advisory-committees/updated-agenda-information-july-25-2024-meeting-oncologic-drugs-advisory-committee-meeting
- FDA advisory committee calendar: "VOTE: Should FDA require that new trial design proposals for perioperative regimens for resectable NSCLC include adequate within trial assessment of contribution of treatment phase? Vote Result: Yes: 11 No: 0 Abstain: 0" https://www.fda.gov/media/183248/download

### August 15, 2024: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "BLA761069 SUPPL-43 (Efficacy): submission_status AP, submission_status_date 20240815, review_priority STANDARD; sponsor_name ASTRAZENECA UK LTD; product IMFINZI (DURVALUMAB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761069%22

### December 4, 2024: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "BLA761069 SUPPL-49 (Efficacy): submission_status AP, submission_status_date 20241204, review_priority PRIORITY; sponsor_name ASTRAZENECA UK LTD; product IMFINZI (DURVALUMAB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761069%22

### February 28, 2025: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "BLA761069 SUPPL-51 (Efficacy): submission_status AP, submission_status_date 20250228, review_priority STANDARD; sponsor_name ASTRAZENECA UK LTD; product IMFINZI (DURVALUMAB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761069%22

### March 28, 2025: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "BLA761069 SUPPL-50 (Efficacy): submission_status AP, submission_status_date 20250328, review_priority PRIORITY; sponsor_name ASTRAZENECA UK LTD; product IMFINZI (DURVALUMAB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761069%22

### June 16, 2025: primary completion

- Status: completed. Date confidence: exact. Stage: 3. Indication: Non-Muscle- Invasive Bladder Cancer.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05943106 (BCG in Combination With Durvalumab in Adult BCG-naïve, High-risk NMIBC Participants): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2025-06-16 (ACTUAL); Lead Sponsor AstraZeneca." https://clinicaltrials.gov/study/NCT05943106

### October 2, 2025: primary completion

- Status: completed. Date confidence: exact. Stage: 3. Indication: Biliary Tract Cancer.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05771480 (Durvalumab With Chemotherapy as First Line Treatment in Patients With Advanced Biliary Tract Cancers (aBTCs)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2025-10-02 (ACTUAL); Lead Sponsor AstraZeneca." https://clinicaltrials.gov/study/NCT05771480

### October 6, 2025: primary completion

- Status: completed. Date confidence: exact. Stage: 3. Indication: Advanced or Metastatic Non-Small Cell Lung Cancer.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05450692 (A Phase III Study of Ceralasertib Plus Durvalumab Versus Docetaxel in Patients With Non Small Cell Lung Cancer (NSCLC) Whose Disease Progressed On or After Prior Anti PD (L)1 Therapy And Platinum Based Chemotherapy): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2025-10-06 (ACTUAL); Lead Sponsor AstraZeneca." https://clinicaltrials.gov/study/NCT05450692

### November 25, 2025: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "BLA761069 SUPPL-52 (Efficacy): submission_status AP, submission_status_date 20251125, review_priority PRIORITY; sponsor_name ASTRAZENECA UK LTD; product IMFINZI (DURVALUMAB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761069%22

### December 31, 2025: primary completion

- Status: completed. Date confidence: exact. Stage: 3. Indication: Papillary Renal Cell Carcinoma.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05043090 (Savolitinib Plus Durvalumab Versus Sunitinib and Durvalumab Monotherapy in MET-Driven, Unresectable and Locally Advanced or Metastatic PRCC): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2025-12-31 (ACTUAL); Lead Sponsor AstraZeneca." https://clinicaltrials.gov/study/NCT05043090

### January 12, 2026: primary completion

- Status: completed. Date confidence: exact. Stage: 2. Indication: Non-small Cell Lung Cancer.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05925530 (Study to Assess Neoadjuvant Durvalumab (D) and Platinum-Based Chemotherapy (CT), Followed by Either Surgery and Adjuvant D or CRT and Consolidation D, in Resectable or Borderline Resectable Stage IIB-IIIB NSCLC (MDT-BRIDGE)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-01-12 (ACTUAL); Lead Sponsor AstraZeneca." https://clinicaltrials.gov/study/NCT05925530

### February 23, 2026: primary completion

- Status: completed. Date confidence: exact. Stage: 3. Indication: Hepatocellular Carcinoma.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05301842 (Evaluate Durvalumab and Tremelimumab +/- Lenvatinib in Combination With TACE in Patients With Locoregional HCC): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-02-23 (ACTUAL); Lead Sponsor AstraZeneca." https://clinicaltrials.gov/study/NCT05301842

### March 2, 2026: primary completion

- Status: completed. Date confidence: exact. Stage: 3. Indication: Muscle Invasive Bladder Cancer.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT04960709 (Treatment Combination of Durvalumab, Tremelimumab and Enfortumab Vedotin or Durvalumab and Enfortumab Vedotin in Patients With Muscle Invasive Bladder Cancer Ineligible to Cisplatin or Who Refuse Cisplatin): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-03-02 (ACTUAL); Lead Sponsor AstraZeneca." https://clinicaltrials.gov/study/NCT04960709

### March 30, 2026: primary completion

- Status: completed. Date confidence: exact. Stage: 3. Indication: Advanced Hepatocellular Carcinoma.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05883644 (Durvalumab and Tremelimumab as First Line Treatment in Participants With Advanced Hepatocellular Carcinoma (HCC)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-03-30 (ACTUAL); Lead Sponsor AstraZeneca." https://clinicaltrials.gov/study/NCT05883644

### May 4, 2026: primary completion

- Status: completed. Date confidence: exact. Stage: 2. Indication: Non-Small Cell Lung Cancer.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06606847 (A Study to Investigate the Effects of Durvalumab With Oleclumab Following Chemoradiation in Participants With Locally Advanced Unresectable Non-Small Cell Lung Cancer (LADOGA)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-05-04 (ACTUAL); Lead Sponsor AstraZeneca." https://clinicaltrials.gov/study/NCT06606847

### May 15, 2026: primary completion

- Status: completed. Date confidence: exact. Stage: 3. Indication: Hepatocellular Carcinoma.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT03847428 (Assess Efficacy and Safety of Durvalumab Alone or Combined With Bevacizumab in High Risk of Recurrence HCC Patients After Curative Treatment): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-05-15 (ACTUAL); Lead Sponsor AstraZeneca." https://clinicaltrials.gov/study/NCT03847428

### May 28, 2026: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "BLA761069 SUPPL-53 (Efficacy): submission_status AP, submission_status_date 20260528, review_priority STANDARD; sponsor_name ASTRAZENECA UK LTD; product IMFINZI (DURVALUMAB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761069%22

### June 1, 2026: primary completion

- Status: completed. Date confidence: exact. Stage: 3. Indication: Unresectable Locally Advanced Urothelial Cancer; Metastatic Urothelial Cancer.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT03682068 (Study of Durvalumab Given With Chemotherapy, Durvalumab in Combination With Tremelimumab Given With Chemotherapy, or Chemotherapy in Patients With Unresectable Urothelial Cancer): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-06-01 (ACTUAL); Lead Sponsor AstraZeneca." https://clinicaltrials.gov/study/NCT03682068

### June 30, 2026: primary completion

- Status: completed. Date confidence: exact. Stage: 2. Indication: Hepatocellular Carcinoma (HCC).
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06040099 (A US Study to Evaluate Transarterial Radioembolization (TARE) in Combination With Durvalumab and Bevacizumab Therapy in People With Unresectable Hepatocellular Carcinoma Amenable to TARE): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-06-30 (ACTUAL); Lead Sponsor AstraZeneca." https://clinicaltrials.gov/study/NCT06040099

### August 10, 2026: primary completion

- Status: completed. Date confidence: exact. Stage: 3. Indication: Non-Small Cell Lung Cancer.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05211895 (A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLC): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-08-10 (ACTUAL); Lead Sponsor AstraZeneca." https://clinicaltrials.gov/study/NCT05211895

### Aug to Nov 2026: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Non-Small Cell Lung Cancer.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05211895 (A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLC): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-08-10 (ACTUAL); Lead Sponsor AstraZeneca." https://clinicaltrials.gov/study/NCT05211895

### Sep to Dec 2026: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Hepatocellular Carcinoma.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05557838 (Durvalumab Plus Tremelimumab as First-line Treatment in Chinese Patients With uHCC): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-09-30 (ESTIMATED); Lead Sponsor AstraZeneca." https://clinicaltrials.gov/study/NCT05557838

### September 2026: primary completion

- Status: delayed. Date confidence: month. Stage: 3. Indication: Hepatocellular Carcinoma.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05557838 (Durvalumab Plus Tremelimumab as First-line Treatment in Chinese Patients With uHCC): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-09-30 (ESTIMATED); Lead Sponsor AstraZeneca." https://clinicaltrials.gov/study/NCT05557838

### Oct 2026 to Jan 2027: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2. Indication: Carcinoma, Non-Small-Cell Lung.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06008093 (A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic NSCLC Patients With Non-squamous Histology Who Have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-10-27 (ESTIMATED); Lead Sponsor AstraZeneca." https://clinicaltrials.gov/study/NCT06008093

### October 2026: primary completion

- Status: delayed. Date confidence: month. Stage: 2. Indication: Carcinoma, Non-Small-Cell Lung.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06008093 (A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic NSCLC Patients With Non-squamous Histology Who Have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-10-27 (ESTIMATED); Lead Sponsor AstraZeneca." https://clinicaltrials.gov/study/NCT06008093

### Nov 2026 to Feb 2027: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2. Indication: Hepatocellular Carcinoma.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07081633 (Durvalumab and Tremelimumab With Lenvatinib as First-line Treatment in Patients With Unresectable Hepatocellular Carcinoma): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-11-30 (ESTIMATED); Lead Sponsor AstraZeneca." https://clinicaltrials.gov/study/NCT07081633

### November 2026: primary completion

- Status: scheduled. Date confidence: month. Stage: 2. Indication: Hepatocellular Carcinoma.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07081633 (Durvalumab and Tremelimumab With Lenvatinib as First-line Treatment in Patients With Unresectable Hepatocellular Carcinoma): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-11-30 (ESTIMATED); Lead Sponsor AstraZeneca." https://clinicaltrials.gov/study/NCT07081633

### Dec 2026 to Mar 2027: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Cancer.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05303532 (Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Durvalumab): Overall Status ENROLLING_BY_INVITATION; Phase PHASE3; Primary Completion 2026-12-31 (ESTIMATED); Lead Sponsor AstraZeneca." https://clinicaltrials.gov/study/NCT05303532

### December 2026: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Cancer.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05303532 (Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Durvalumab): Overall Status ENROLLING_BY_INVITATION; Phase PHASE3; Primary Completion 2026-12-31 (ESTIMATED); Lead Sponsor AstraZeneca." https://clinicaltrials.gov/study/NCT05303532

### Jan to Apr 2027: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Non-Small Cell Lung Cancer.
- First seen 2026-11-12, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05221840 (A Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-01-08 (ESTIMATED); Lead Sponsor AstraZeneca." https://clinicaltrials.gov/study/NCT05221840
- SEC Form 10-Q (accession 0001493152-26-051439): "AIM anticipates topline results in the first quarter of 2027, followed by the analysis of overall survival in the third quarter of 2027." https://www.sec.gov/Archives/edgar/data/946644/000149315226051439/form10-q.htm

### Jan to Apr 2027: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2. Indication: Lung Cancer.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05374603 (Savolitinib Combine With Durvalumab in EGFR Wild-type Locally Advanced or Metastatic NSCLC): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-01-18 (ESTIMATED); Lead Sponsor AstraZeneca." https://clinicaltrials.gov/study/NCT05374603

### January 2027: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Non-Small Cell Lung Cancer.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05221840 (A Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-01-08 (ESTIMATED); Lead Sponsor AstraZeneca." https://clinicaltrials.gov/study/NCT05221840

### January 2027: primary completion

- Status: scheduled. Date confidence: month. Stage: 2. Indication: Lung Cancer.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05374603 (Savolitinib Combine With Durvalumab in EGFR Wild-type Locally Advanced or Metastatic NSCLC): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-01-18 (ESTIMATED); Lead Sponsor AstraZeneca." https://clinicaltrials.gov/study/NCT05374603

### May to Aug 2027: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2. Indication: Gastric Cancer.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT04379596 (Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-05-04 (ESTIMATED); Lead Sponsor AstraZeneca." https://clinicaltrials.gov/study/NCT04379596

### May 2027: primary completion

- Status: scheduled. Date confidence: month. Stage: 2. Indication: Gastric Cancer.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT04379596 (Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-05-04 (ESTIMATED); Lead Sponsor AstraZeneca." https://clinicaltrials.gov/study/NCT04379596

### Jun to Sep 2027: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Esophageal Squamous Cell Carcinoma.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT04550260 (Study of Durvalumab Versus Placebo in Combination With Definitive Chemoradiation Therapy in Patient With ESCC): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-06-30 (ESTIMATED); Lead Sponsor AstraZeneca." https://clinicaltrials.gov/study/NCT04550260

### June 2027: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Esophageal Squamous Cell Carcinoma.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT04550260 (Study of Durvalumab Versus Placebo in Combination With Definitive Chemoradiation Therapy in Patient With ESCC): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-06-30 (ESTIMATED); Lead Sponsor AstraZeneca." https://clinicaltrials.gov/study/NCT04550260

### Jul to Oct 2027: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Breast Cancer.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06103864 (A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-07-28 (ESTIMATED); Lead Sponsor AstraZeneca." https://clinicaltrials.gov/study/NCT06103864

### July 2027: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Breast Cancer.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06103864 (A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-07-28 (ESTIMATED); Lead Sponsor AstraZeneca." https://clinicaltrials.gov/study/NCT06103864

### September 2027: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Breast Cancer.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05629585 (A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-09-01 (ESTIMATED); Lead Sponsor AstraZeneca." https://clinicaltrials.gov/study/NCT05629585

### Sep to Dec 2027: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Breast Cancer.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05629585 (A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-09-01 (ESTIMATED); Lead Sponsor AstraZeneca." https://clinicaltrials.gov/study/NCT05629585

### November 2027: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: NSCLC.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05687266 (Phase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic Alterations): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-11-01 (ESTIMATED); Lead Sponsor AstraZeneca." https://clinicaltrials.gov/study/NCT05687266

### Nov 2027 to Feb 2028: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: NSCLC.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05687266 (Phase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic Alterations): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-11-01 (ESTIMATED); Lead Sponsor AstraZeneca." https://clinicaltrials.gov/study/NCT05687266

### Jun to Sep 2028: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Biliary Tract Cancer.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06467357 (Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-06-12 (ESTIMATED); Lead Sponsor AstraZeneca." https://clinicaltrials.gov/study/NCT06467357

### June 2028: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Biliary Tract Cancer.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06467357 (Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-06-12 (ESTIMATED); Lead Sponsor AstraZeneca." https://clinicaltrials.gov/study/NCT06467357

### Aug to Nov 2028: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2. Indication: Urinary Bladder Neoplasms; Immune Checkpoint Inhibitors; Methotrexate.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06960577 (Perioperative Durvalumab With Neoadjuvant ddMVAC in Patients With Muscle-Invasive Bladder Cancer (NIAGARA-2)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-08-30 (ESTIMATED); Lead Sponsor AstraZeneca." https://clinicaltrials.gov/study/NCT06960577

### August 2028: primary completion

- Status: scheduled. Date confidence: month. Stage: 2. Indication: Urinary Bladder Neoplasms; Immune Checkpoint Inhibitors; Methotrexate.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06960577 (Perioperative Durvalumab With Neoadjuvant ddMVAC in Patients With Muscle-Invasive Bladder Cancer (NIAGARA-2)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-08-30 (ESTIMATED); Lead Sponsor AstraZeneca." https://clinicaltrials.gov/study/NCT06960577

### Oct 2028 to Jan 2029: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Carcinoma, Non-Small-Cell Lung.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT03833154 (Durvalumab With Stereotactic Body Radiation Therapy (SBRT) vs Placebo With SBRT in Early Stage Unresected Non-small Cell Lung Cancer (NSCLC) Patients/ Osimertinib Following SBRT in Patients With Early Stage Unresected NSCLC Harboring an EGFR Mutation): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-10-31 (ESTIMATED); Lead Sponsor AstraZeneca." https://clinicaltrials.gov/study/NCT03833154

### October 2028: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Carcinoma, Non-Small-Cell Lung.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT03833154 (Durvalumab With Stereotactic Body Radiation Therapy (SBRT) vs Placebo With SBRT in Early Stage Unresected Non-small Cell Lung Cancer (NSCLC) Patients/ Osimertinib Following SBRT in Patients With Early Stage Unresected NSCLC Harboring an EGFR Mutation): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-10-31 (ESTIMATED); Lead Sponsor AstraZeneca." https://clinicaltrials.gov/study/NCT03833154

### Nov 2028 to Feb 2029: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Breast Cancer.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06112379 (A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-11-20 (ESTIMATED); Lead Sponsor AstraZeneca." https://clinicaltrials.gov/study/NCT06112379

### November 2028: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Breast Cancer.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06112379 (A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-11-20 (ESTIMATED); Lead Sponsor AstraZeneca." https://clinicaltrials.gov/study/NCT06112379

### Jun to Sep 2029: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Small Cell Lung Carcinoma.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06992609 (Durvalumab After Chemoradiotherapy in Limited Stage Small Cell Lung Cancer.): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2029-06-30 (ESTIMATED); Lead Sponsor AstraZeneca." https://clinicaltrials.gov/study/NCT06992609

### June 2029: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Small Cell Lung Carcinoma.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06992609 (Durvalumab After Chemoradiotherapy in Limited Stage Small Cell Lung Cancer.): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2029-06-30 (ESTIMATED); Lead Sponsor AstraZeneca." https://clinicaltrials.gov/study/NCT06992609

### Jul to Oct 2029: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Biliary Tract Cancer.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07221253 (A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-07-31 (ESTIMATED); Lead Sponsor AstraZeneca." https://clinicaltrials.gov/study/NCT07221253

### July 2029: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Biliary Tract Cancer.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07221253 (A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-07-31 (ESTIMATED); Lead Sponsor AstraZeneca." https://clinicaltrials.gov/study/NCT07221253

### November 2029: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Gastric; Esophagogastric Junction.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07877818 (A Study of Neoadjuvant-adjuvant Durvalumab and FLOT Chemotherapy Followed by Adjuvant Durvalumab in Chinese Patients With Resectable GC/GEJC.): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-11-01 (ESTIMATED); Lead Sponsor AstraZeneca." https://clinicaltrials.gov/study/NCT07877818

### Nov 2029 to Feb 2030: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Gastric; Esophagogastric Junction.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07877818 (A Study of Neoadjuvant-adjuvant Durvalumab and FLOT Chemotherapy Followed by Adjuvant Durvalumab in Chinese Patients With Resectable GC/GEJC.): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-11-01 (ESTIMATED); Lead Sponsor AstraZeneca." https://clinicaltrials.gov/study/NCT07877818

### May to Aug 2030: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2. Indication: Non-small Cell Lung Cancer.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05061550 (Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2030-05-28 (ESTIMATED); Lead Sponsor AstraZeneca." https://clinicaltrials.gov/study/NCT05061550

### May 2030: primary completion

- Status: scheduled. Date confidence: month. Stage: 2. Indication: Non-small Cell Lung Cancer.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05061550 (Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2030-05-28 (ESTIMATED); Lead Sponsor AstraZeneca." https://clinicaltrials.gov/study/NCT05061550

### Sep to Dec 2030: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: High-risk Muscle Invasive Urothelial Carcinoma.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07720284 (An Open-label Study to Investigate the Efficacy and Safety of Dato-DXd + Rilvegostomig vs SoC in Adult Participants With High-risk MIUC): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2030-09-11 (ESTIMATED); Lead Sponsor AstraZeneca." https://clinicaltrials.gov/study/NCT07720284

### September 2030: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: High-risk Muscle Invasive Urothelial Carcinoma.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07720284 (An Open-label Study to Investigate the Efficacy and Safety of Dato-DXd + Rilvegostomig vs SoC in Adult Participants With High-risk MIUC): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2030-09-11 (ESTIMATED); Lead Sponsor AstraZeneca." https://clinicaltrials.gov/study/NCT07720284

## Same indication

- [ABBV-1480](https://sec-api.dev/pdufa/abbv-1480) (ABBV)
- [Adi-peg20](https://sec-api.dev/pdufa/adi-peg20) (PII)
- [Piqray (alpelisib)](https://sec-api.dev/pdufa/alpelisib) (NVS)
- [Arm a: gedatolisib + palbociclib + fulvestrant](https://sec-api.dev/pdufa/arm-a-gedatolisib-palbociclib-fulvestrant) (CELC)
- [Bgb-b2033](https://sec-api.dev/pdufa/bgb-b2033) (ONC)
- [Budigalimab](https://sec-api.dev/pdufa/budigalimab) (ABBV)
- [Truqap (capivasertib)](https://sec-api.dev/pdufa/capivasertib) (AZN)
- [Casdozokitug](https://sec-api.dev/pdufa/casdozokitug) (CHRS)
- [CTX-009](https://sec-api.dev/pdufa/ctx-009) (CMPX)
- [Dato-dxd](https://sec-api.dev/pdufa/dato-dxd) (AZN)
- [Durvalumab (imfinzi) immunotherapy](https://sec-api.dev/pdufa/durvalumab-imfinzi-immunotherapy) (BSX)
- [Revtorpyk (gedatolisib)](https://sec-api.dev/pdufa/gedatolisib) (CELC)
- [Ivonescimab](https://sec-api.dev/pdufa/ivonescimab) (SMMT)
- [Iza-bren](https://sec-api.dev/pdufa/iza-bren) (BMY)
- [JDQ443](https://sec-api.dev/pdufa/jdq443) (NVS)
- [Livmoniplimab](https://sec-api.dev/pdufa/livmoniplimab) (ABBV)
- [N-803 + pembrolizumab](https://sec-api.dev/pdufa/n-803-pembrolizumab) (IBRX)
- [Namodenoson](https://sec-api.dev/pdufa/namodenoson) (CANF)
- [Palazestrant](https://sec-api.dev/pdufa/palazestrant) (OLMA)
- [IBRANCE® (palbociclib)](https://sec-api.dev/pdufa/palbociclib) (PFE)
- [Pcs6422 and capecitabine](https://sec-api.dev/pdufa/pcs6422-and-capecitabine) (PCSA)
- [PF-07220060](https://sec-api.dev/pdufa/pf-07220060) (PFE)
- [PF-07248144](https://sec-api.dev/pdufa/pf-07248144) (PFE)
- [Plinabulin](https://sec-api.dev/pdufa/plinabulin) (BYSI)
- [Rilvegostomig](https://sec-api.dev/pdufa/rilvegostomig) (AZN)
- [Rp2](https://sec-api.dev/pdufa/rp2) (REPL)
- [Sigvotatug vedotin](https://sec-api.dev/pdufa/sigvotatug-vedotin) (PFE)
- [Sv-br-1-gm](https://sec-api.dev/pdufa/sv-br-1-gm) (BCTX)
- [Telisotuzumab adizutecan](https://sec-api.dev/pdufa/telisotuzumab-adizutecan) (ABBV)
- [TPST-1120](https://sec-api.dev/pdufa/tpst-1120) (TPST)
- [Tremelimumab](https://sec-api.dev/pdufa/tremelimumab) (AZN)
- [Volrustomig](https://sec-api.dev/pdufa/volrustomig) (AZN)
- [VS-7375](https://sec-api.dev/pdufa/vs-7375) (VSTM)
- [Ziihera® (zanidatamab)](https://sec-api.dev/pdufa/zanidatamab) (JAZZ)

Calendar months: [September 2026](https://sec-api.dev/fda-calendar/2026-09), [October 2026](https://sec-api.dev/fda-calendar/2026-10), [November 2026](https://sec-api.dev/fda-calendar/2026-11), [December 2026](https://sec-api.dev/fda-calendar/2026-12), [January 2027](https://sec-api.dev/fda-calendar/2027-01), [May 2027](https://sec-api.dev/fda-calendar/2027-05), [June 2027](https://sec-api.dev/fda-calendar/2027-06), [July 2027](https://sec-api.dev/fda-calendar/2027-07), [September 2027](https://sec-api.dev/fda-calendar/2027-09), [November 2027](https://sec-api.dev/fda-calendar/2027-11), [June 2028](https://sec-api.dev/fda-calendar/2028-06), [August 2028](https://sec-api.dev/fda-calendar/2028-08), [October 2028](https://sec-api.dev/fda-calendar/2028-10), [November 2028](https://sec-api.dev/fda-calendar/2028-11)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/durvalumab.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Imfinzi® (durvalumab) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/durvalumab

```bibtex
@misc{secapidev_pdufa_durvalumab_20261116,
  title        = {Imfinzi® (durvalumab) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/durvalumab}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_durvalumab_20261116","title":"Imfinzi® (durvalumab) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/durvalumab","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
